Investor Presentaiton

Creating Value, Continuously... Began with 5 products CARACO DUSA • URL PHARMA a SUN PHARMA company • $7.5Mn TARO invested in Caraco Acquired Dusa Acquired URL Acquired Taro Pharma • Licensing agreement with Almirall for Tildrakizumab in Europe for Psoriasis Announced positive results from Phase-3 trials for Tildrakizumab SUN PHARMA Entry into Japan -Acquired 14 brands from Novartis Acquired Biosintez in Russia Acquired Global rights for OTX-101 & Odomzo BromSite launch in US Year 1983 1994 1997 2010 2012 2013 2014 2015 2016 2017 2018 Market Cap (US$ 0.1 0.1 7.8 12.3 15.6 19.7 34.6 30.0 25.5 18.3 Bn) as of Mar, 31 of respective years - IPO Rs. 550 Mn raised MERCK Agreement with Merck for in- licensing Tildrakizumab RANBAXY LABORATORIES LIMITED Acquired Ranbaxy Sun Pharma Today 30,000+ Employees Invested over Rs 130 Bn in R&D till date © Sun Pharmaceutical Industries Limited. All Rights Reserved. • US FDA approval InSite Vision Solutions for Sight Acquired InSite Vision ophthalmic portfolio • for Ilumya & Yonsa Announced positive Phase-3 results for OTX-101 & filed NDA with USFDA • Tildrakizumab filing in US & Europe • Launched Odomzo in US BSE SENSEX NIFTY Stock of the nation Part of NSE Nifty & BSE Sensex in India 41 Manufacturing facilities in 6 Continents 68% of sales from international markets 13

View entire presentation